BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Cardiovascular disease (CVD) mortality increased by 78%, rising from 72.4 to 128.7 per 100 000 (2017–2022), with the greatest ...

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight ...

Evidence of myocardial injury does not necessitate a diagnosis of myocarditis. When a cardiac troponin level is over the 99th percentile of the upper reference limit, 6 there exists a spectrum of ...

BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...

Using the Global Burden of Disease 2021 data, we analyzed the prevalence and disability‐adjusted life years, examining implications across demographics and geographic regions. In 2021, an estimated 54 ...

Although heart transplantation is the preferred therapy for appropriate patients with advanced heart failure, the presence of concomitant renal or hepatic dysfunction can pose a barrier to isolated ...

Circulation: Arrhythmia and Electrophysiology A specialized journal dedicated to advancing the understanding and management of cardiac arrhythmias and electrophysiology Editor-in-Chief: Paul J. Wang, ...

Cardiovascular disease (CVD) is the predominant cause of death globally, accounting for ≈30% of deaths each year. 1 The prevalence of CVD among adults (aged ≥20 years) in the United States was 48.6% ...

Low diet quality in the United States reflects a multitude of factors, 2 of which are food insecurity and nutrition insecurity. Food insecurity is defined as having insufficient access to enough food ...

BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment–elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI).